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1 Introduction 
Cystic Fibrosis is a genetic disorder which occurs due to mutations in the CF transmembrane conductance 
regulator gene (cftr). The gene has two key functions in chloride ion transport. The first is to mediate 
chloride ion conduction across the cell membrane. The second is to activate chloride ion channel activity 
(Dorwart et al 2004). Mutations in this gene result in reduced chloride secretion into the airways and 
increased absorption of sodium from the airways. This, in turn, results in a viscous airway mucous which 
adversely affects mucociliary clearance. The outcome is persistent mucin secretion and the formation of 
mucous plugs. The mucous plugs are a focus for persistent bacterial infections. (Boucher 2002)   
Patients with cystic fibrosis may be infected with respiratory commensals or opportunistic pathogens. 
Among the organisms commonly isolated are Haemophilus influenzae, Staphylococcus aureus, 
Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, Alcaligenes 
xylosoxidans, Aspergillus fumigatus and non-tuberculous mycobacteria. Historically, Staphylococcus aureus 
and Pseudomonas aeruginosa were the organisms most prevalent in this population. Recently, some of the 
other pathogens mentioned have emerged globally.  A number of reports across the globe have described the 
prevalence of each organism mentioned above. However, the prevalence differs from country to country and 
sometimes even from one centre to another (de Vrankrijker et al 2010). Thus management guidelines differ 
based on the findings of prevalence studies in each centre or country. A brief description of each of the 
aforementioned pathogens follows, with particular attention to prevalence, both overall and age-specific, 
changes in prevalence over time and antimicrobial resistance.  
 
Haemophilus influenzae 
Haemophilus influenzae is a pleomorphic gram negative bacillus usually implicated in respiratory 
infections, bacteraemia and meningitis in infants and young children. In cystic fibrosis, it is a common 
commensal of the respiratory tract of young children. The prevalence is at its peak in the 2- 5 year age group 
and decreases until adulthood (LiPuma 2010). It has been found that non-encapsulated Haemophilus 
influenzae is associated with chronic infections of the lung in cystic fibrosis patients. Exposure to multiple 
courses of antibiotics during the first few years of life leads to the development of multi-drug resistance in 
this pathogen (Cardines et al 2012).   
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Staphylococcus aureus 
Staphylococcus aureus is a gram positive coccus implicated in a wide spectrum of infections including those 
of the skin and soft tissue, bone and joints, prosthetic devices, lung, bloodstream and central nervous 
system. In cystic fibrosis, Staphylococcus aureus is often the first pathogen recovered from respiratory 
secretions. Studies conducted in the USA through the Cystic Fibrosis Foundation have demonstrated the 
highest prevalence of Staphylococcus aureus in children between 6-10 years of age (LiPuma 2010). In more 
recent years, the problem of methicillin resistant  Staphylococcus aureus (MRSA) has emerged as a 
worldwide problem, both in the healthcare setting, as well as in the community setting. The prevalence of 
MRSA in the cystic fibrosis population has mirrored this and is well described internationally (LiPuma 
2010). Studies in the USA have noted an increased prevalence in children between 6 and 17 years of age 
(Razvi 2009).  However, studies in the Netherlands have shown low rates of MRSA in their cystic fibrosis 
population as a result of strict MRSA infection control policies (de Vrankrijker et al 2010).  
 
Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a non-fermentative gram negative bacillus which is ubiquitous in the 
environment. It is regarded as the most important pathogen in cystic fibrosis. Colonisation is initially 
intermittent, but gradually becomes persistent and chronic (Li et al 2005). With the establishment of chronic 
infection, the phenotype of the organism converts to a mucoid variety. This mucoid phenotype confers 
resistance to multiple antibiotics, making eradication difficult (Vrankrijker et al 2010).  The prevalence of 
the organism increases with age, although the initial infection usually occurs soon after birth. Recent data 
from international studies have demonstrated conflicting results regarding changes in the prevalence of 
Pseudomonas aeruginosa. Some areas have described decreases in prevalence, whereas others have noted 
no change in prevalence (Razvi et al 2009; Millar et al 2009).  
 
Burkholderia cepacia complex 
This gram negative bacillus is also ubiquitous in the environment. The complex consists of 17 closely 
related species. It emerged as a pathogen in the 1980’s and is today a well recognized pathogen in cystic 
fibrosis patients. The clinical course is variable and ranges from asymptomatic; to prolonged progressive 
deterioration; to rapid fulminant and often fatal deterioration.  As with the aforementioned pathogens, the 
prevalence of Burkholderia cepacia differs from country to country, with the USA reporting a decrease in 
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prevalence during the late 1990’s, the UK reporting an increase during the 1990’s but a decline during the 
early 2000’s and very low and consistent rates described in the Netherlands (Razvi et al 2009; Millar et al 
2008; de Vrankrijker et al 2010). Once again, age specific prevalence has been noted, with higher 
prevalence in older patients (LiPuma 2010).  
 
Stenotrophomonas maltophilia 
Stenotrophomonas maltophilia is a gram negative opportunistic pathogen with intrinsic resistance to 
commonly used broad-spectrum  antimicrobials, including carbapenems. It is a well known cause of a 
variety of opportunistic infections in immune-compromised patients, including pneumonia, bacteraemia, 
urinary tract infections, endocarditis, eye infections, bone and soft tissue infections and peritonitis.  Recent 
reports indicate that infections due to this pathogen have increased. As with the increase in MRSA, the 
prevalence of Stenotrophomonas maltophilia has also increased among cystic fibrosis patients in recent 
years (Ballestero et al 1995; Talmaciu et al 2000). The recent emergence of this pathogen has been 
associated with the use of anti-pseudomonal antibiotics in cystic fibrosis (de Vrankrijker et al 2010). In 
particular, the use of quinolones has been found to be a risk factor for infection with Stenotrophomonas 
maltophilia in the cystic fibrosis population (Talmaciu et al. 2000).  Unlike the persistent infection with 
Pseudomonas aeruginosa and Burkholderia cepacia, colonization with Stenotrophomonas maltophilia is 
usually intermittent (Demko et al 1998). Clinical development of resistance to the few antibiotics active 
against this pathogen has not been documented, and an in vitro study which examined a series of  pre and 
post-treatment isolates of Stenotrophomonas maltophilia from cystic fibrosis patients demonstrated no 
increase in resistance development (San Gabriel et al 2004).  
 
Alcaligenes xylosoxidans  
This gram negative bacillus is similar to Stenotrophomonas maltophilia in that it is an opportunistic 
pathogen which causes nosocomial infections. In cystic fibrosis patients, the true prevalence is difficult to 
determine, since studies have shown broadly differing rates of infection (LiPuma 2010). Alcaligenes 
xylosoxidans is often a transient, although chronic infection may occur (Moissenet D A et al 1997).  
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Aspergillus fumigatus 
Aspergillus fumigatus is the most common filamentous fungus involved in Cystic Fibrosis. Infection with 
this mould results in a chronic allergic inflammatory response known as allergic bronchopulmonary 
aspergillosis (LiPuma 2010). Patients usually present with a worsening of lung function. Many global cystic 
fibrosis centres have reported the prevalence of Aspergillus fumigatus and the range reported has increased 
over the last 2 decades, possibly as a result of improvements in culture methods and frequency of culturing. 
(Bakare N et al 2003; Valenza G et al 2008). Studies which have looked at prevalence by age stratification 
have noted increased prevalence with increased age (LiPuma 2010).  
 
Non-tuberculous Mycobacteria 
These mycobacteria are widely distributed in the environment. The most common species are 
Mycobacterium avium  and Mycobacterium abscessus complex (de Vrankrijker et al 2010). These organisms 
were first isolated among cystic fibrosis patients in the 1970’s (LiPuma 2010). The reported prevalence in 
cystic fibrosis patients ranges from <5% to almost 30% (de Vrankrijker et al 2010; LiPuma 2010). Age 
specific prevalence studies have reported lower rates in children less than 15 years of age (LiPuma 2010).   
A recent study reported that Mycobacterium avium and Mycobacterium abscessus complex target different 
cystic fibrosis patient subgroups. Mycobacterium avium was found in older patients as opposed to 
Mycobacterium abscessus complex, and Mycobacterium avium infected patients were usually diagnosed 
later in life. Patients infected with Mycobacterium abscessus complex received intravenous antibiotics prior 
to isolation of the pathogen and were often co-colonised with Aspergillus spp. (Catherinot et al 2012).  
 
Much information is available globally regarding pathogens which chronically or intermittently infect 
patients with cystic fibrosis. However, no such data seems to be available from South Africa. Therefore, the 
aim of this study is to report on the range of respiratory pathogens infecting the cystic fibrosis population, to 
describe race and age-specific trends as well as to document prevalence and changes in antimicrobial 
resistance amongst these pathogens. This information may assist with development of empiric treatment 
policies in the unit. It may also better guide infection control policies in the unit to prevent transmission of 
multi-drug resistant pathogens among this population of immune-compromised patients.  
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2 Significance of the Study 
No data regarding the pathogens infecting the cystic fibrosis population is currently available in South 
Africa. Knowledge of infecting pathogens and antimicrobial resistance among these pathogens will likely 
assist with development of future management guidelines as well as better direct infection prevention and 
control efforts against these pathogens. 
 
3 Definitions 
 Colonisation: 1 culture positive for an organism in a patient who has had >1 specimen submitted to 
the NHLS laboratory 
 Chronic colonization: ≥ 2 cultures positive for the same organism during a 6 month period 
 Intermittent colonization: > 1 culture positive for the same organism which does not meet the criteria 
for chronic colonization 
 Age Category: The patient’s age on 31 December of each year will determine which age category 
he/she will fall into for analysis of age- specific prevalence 
 National Health Laboratory Service (NHLS): As South Africa’s largest diagnostic pathology service 
the NHLS is responsible for providing laboratory services to > 80% of South Africa’s population 
through a national system of laboratories. 
 Disa System: The NHLS laboratory information system (LIS) onto which all patient results are 
loaded.  
4 Study Aim and Objectives 
4.1 Aim 
The aim of this study is to describe the  respiratory microbiology of patients attending the CMJAH 
cystic fibrosis clinic. 
4.2 Objectives 
4.2.1 Primary Objectives 
 To describe the prevalence of the above- mentioned organisms among the cystic fibrosis population 
at  Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) during the study period. 
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 To describe the prevalence of antimicrobial resistance among the above-mentioned organisms 
during the study period. 
 To determine whether there has been any significant change in prevalence to the above-mentioned 
organisms over the course of the study period. 
 To determine whether there has been any significant change in prevalence of resistance to the 
above- mentioned organisms over the course of the study period 
4.2.2 Secondary Objectives 
 To describe the age-specific prevalence of the above-mentioned organisms among the cystic fibrosis 
population at Charlotte Maxeke Johannesburg Academic Hospital during the study period. 
 To describe the race-specific prevalence of the above-mentioned organisms among the cystic 
fibrosis population at Charlotte Maxeke Johannesburg Academic Hospital during the study period. If 
the number of non-caucasian patients is suboptimal for statistical analysis, this objective may not be 
fulfilled. 
 To describe the age-specific prevalence of antimicrobial resistance among the above-mentioned 
organisms during the study period. 
 To describe the race-specific prevalence of antimicrobial resistance among the above-mentioned 
organisms during the study period. If the number of non-caucasian patients is suboptimal for 
statistical analysis, this objective may not be fulfilled. 
4.2.3 Tertiary Objectives 
 To describe co-infection with more than one pathogen. 
 To report on the number of cultures with no growth of micro-organisms and growth only of normal 
commensals. 
 to describe the pattern of colonization of each micro-organism; whether intermittent or chronic 
(refer to definitions) 
 
5 Methods 
5.1 Study Site 
The study will be conducted at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).  
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5.2 Study Population 
The study will be conducted at the cystic fibrosis clinics at the Charlotte Maxeke Hospital.  
5.3 Study Sample 
The study sample will be the total number of patients from the cystic fibrosis clinics at CMJAH who 
meet the inclusion criteria during the period under study. 
5.4 Sample Size 
As this study is a retrospective review, a sample size cannot be calculated, however, an estimate of 100 
patient files will be reviewed. If the number of files investigated is suboptimal for statistical analysis, the 
study period may be extended include file reviews of patients attending the adult cystic fibrosis clinic at 
CMJAH. The study may also be extended to include periods before 2006 and/or after 2010. 
5.5 Inclusion Criteria 
The following inclusion criteria will be used:  
 Every clinic attendee during the period 1 January 2006 to 31 December 2010, who fulfils any one of 
the following requirements: 
o At least one respiratory specimen submitted to the NHLS laboratory for bacterial 
microscopy, culture and sensitivity testing. 
o At least one respiratory specimen submitted to the NHLS laboratory for fungal microscopy, 
culture and sensitivity testing. 
o At least one specimen submitted to the NHLS laboratory for mycobacterial microscopy, 
culture and sensitivity testing.  
5.6 Exclusion criteria 
 Any patient attended to at the cystic fibrosis clinics at Charlotte Maxeke Hospital during the period 1 
January 2006 to 31 December 2010 with no respiratory specimens submitted to the NHLS laboratory 
for bacterial, fungal or mycobacterial microscopy, culture and sensitivity testing. 
 Any patient whose laboratory results cannot be traced. 
 Any patient whose clinical details cannot be traced. 
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5.7 Study Design  
The study design is a cross-sectional, descriptive, retrospective review of respiratory pathogens from 
patients attending the cystic fibrosis clinic. The study will describe the prevalence of specific pathogens 
and the prevalence of resistance to antimicrobials among these pathogens.    
 
5.8 Data Collection  
Data is to be collected on a data collection sheet. The data to be collected can be divided into patient 
specific and pathogen-specific information. 
Patient- specific details will be obtained from patient files at CMJAH cystic fibrosis clinic. 
Pathogen- specific details include micro-organism identity and antimicrobial resistance. Every available 
laboratory result of respiratory samples from these patients submitted to the NHLS laboratory for 
bacterial, fungal and mycobacterial microscopy, culture and sensitivity testing during the period 1 
January 2006- 31 December 2010 will be included in the study. These results will be obtained from 
patient files as well as from the NHLS Disa system.  
 
For details of data to be collected, please refer to Appendix 1 
  
6 Data Capture 
Microsoft Excel spreadsheets will be used to capture the data collected 
For details of data to be captured on Excel, please refer to Appendix 2 
 
7 Statistical Analysis 
Prevalence of organisms and prevalence of antibiotic resistance will be determined using the equations in 
Appendix 3. 
Changes in prevalence and trend analyses will be calculated in consultation with a biostatistician. In 
addition, it is likely that further statistical analysis techniques may provide further insight. These will be 
evaluated and proposed in conjunction with a biostatistician.  
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8 Ethical Considerations 
An Ethics Committee waiver will be obtained from the University of the Witwatersrand Ethics Committee. 
Permission to conduct the study will be obtained from the CMJAH hospital CEO and permission to access 
patient files will be obtained from the head of the CMJAH pediatric cystic fibrosis clinic (Dr. S. Klugman) 
as well as the head of the adult cystic fibrosis clinic (Prof. M. Mer). 
 
The study will be conducted according to the World Medical Association’s Declaration of Helsinki- Ethical 
Principles for Medical Research Involving Human Subjects. 
 
9 Study Timeline  
Protocol submission and Assessment: August- September 2012 
Ethics Review: September 2012 
Data Collection: October – December 2012 
Data capture and statistical analysis: January – March 2012 
Writing of report and writing of publication: April – June 2012 
 
10 Funding 
The costs involved in conducting this study total R1200.00 and will be funded by the Department of 
Clinical Microbiology and Infectious Diseases. The costs include: 
Photocopying: R300.00 
Transport: R700.00 
Stationery: R200.00 
 
No additional costs will be incurred by the University of the Witwatersrand or the Charlotte Maxeke 
Johannesburg Academic Hospital 
 
11 Potential Limitations 
 The study is contextual to the population being investigated. It may not be possible to generalize the 
findings of this study to other regions in South Africa. However, the cystic fibrosis clinics at 
 11 
CMJAH are a large drainage site for the greater Gauteng region, and the findings of this study will 
provide important information regarding pathogens infecting this population of patients.  
 The sample size is expected to be small and this may affect statistical analysis. 
 The scope of the study is limited by time constraints.  
 
12 Anticipated Problems 
 There may be inadequate or incomplete data in patient files. 
 Patient files may be misplaced in the filing system. 
 Illegibility of clinician’s handwriting may compromise the quality of data collected. 
 Patient results may be inaccessible or misplaced. 
 There may be inadequate numbers of non-causcasian patients for the race sub-group analyses 
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14 Appendix 
Appendix 1      
Patient Details 
Name  
Age 
Age Categories: 
1yr 
5yrs 
5- 10yrs 
10- 15yrs 
15- 20yrs 
> 20 yrs 
Race 
White 
Black 
Indian 
Coloured 
Other 
Specimen Type 
Sputum 
Cough Swab 
Throat swab 
Broncho-alveolar lavage 
 
 
Organism cultured and Antibiotics to be 
assessed for Resistance  
 
 
 
 
 
Haemophilus 
influenzae 
HI-b Ampicillin 
Non-type Cefotaxime 
 Meropenem 
Staphylococcus aureus Methicillin 
 
Pseudomonas aeruginosa 
 
 
Piperacillin- Tazobactam 
Ceftazidime 
Cefepime 
Meropenem 
Imipenem 
Gentamicin 
Amikacin 
Tobramycin 
Ciprofloxacin 
Colistin 
Burkholderia cepacia complex 
Trimethoprim-
sulfamethoxazole 
Stenotrophomonas maltophilia 
Trimethoprim-
sulfamethoxazole 
Alcaligenes xylosoxidans  
Aspergillus fumigatus  
Non-tuberculous mycobacteria  
 
 Non-mucoid  
 Mucoid  
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Appendix 2 
 
 
 
 
 
 
 
 
Study Number Age category Race
HI SA PA BCC SM AX AF Other
MAC MASC MK Other
Organism cultured in 2006
NTM
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Year: 
Study Number Age Race Lab Number 
MSSA MRSA
S R S R S R S R S R S R S R S R S R S R S R S R S I R S I R
SA
CTXAMP
HI
MERO CIPRO
PA
TOBAMIKGENTIMIMEROCPMCTZ
SMBCC
COTRICOL
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Appendix 3 
Prevalence Calculations: 
Prevalence of organism X =  
Number of patients with 1st culture positive for organism X      X 100 
Total number of patients attending the clinic in that year 
 
Prevalence of organism X in specific age category =  
Number of patients in age category Z with first culture positive for organism X    X100 
Total number of patients in age category Z attending the clinic in that year 
 
Prevalence of organism X in a specific race group =  
Number of patients in Race Group A with first culture positive for organism X   X100 
Total number of patients in Race Group A attending the clinic in that year 
 
Prevalence of Resistance of antimicrobial Y to organism X  = 
Total number of organism X isolates resistant to antimicrobial Y     X100 
Total number of organism X isolates cultured in that year 
 
Prevalence of Resistance in age category Z of antimicrobial Y to organism X =  
Total number of organism X isolates from age category Z which are resistant to antimicrobial Y  X100 
Total number of organism X isolates cultured from age category Z in that year                                                     
 
Prevalence of Resistance in Race Group A of antimicrobial Y to organism X =  
Total number of organism X isolates in Race Group A which are resistant to antimicrobial Y   X100 
Total number of organism X isolates cultured from Race group A in that year  
